394 related articles for article (PubMed ID: 23063746)
1. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.
Elsayed MS; El-Araby ME; Serya RA; El-Khatib AH; Linscheid MW; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():122-31. PubMed ID: 23063746
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
5. Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment.
Jin F; Gao D; Zhang C; Liu F; Chu B; Chen Y; Chen YZ; Tan C; Jiang Y
Bioorg Med Chem; 2013 Feb; 21(3):824-31. PubMed ID: 23260578
[TBL] [Abstract][Full Text] [Related]
6. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
Yao J; He Z; Chen J; Sun W; Fang H; Xu W
Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
10. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
15. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Shallal HM; Russu WA
Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of novel 7-azaindazolyl-indolyl-maleimide derivatives as antitumor agents and protein kinase C inhibitors.
Ye Q; Cao J; Zhou X; Lv D; He Q; Yang B; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4763-72. PubMed ID: 19447039
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
20. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
